Please assess the completion status of the following clinical trial:

Trial Title: STAAR-2 Clinical Study

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* ≥ 18 years old~* diagnosis of CRI and not receiving dialysis therapy (must be predialysis)~* measured or estimated (using the Cockcroft-Gault formula) creatinine clearance (CrCl) of ≤ 70 mL/min, or GFR ≤ 60 mL/min (using the MDRD formula):~* Cockcroft-Gault formula: CrCl = (140 minus age in years) x (body weight in kg) serum creatinine (mg/dL) x 72.0 For women, the value will be multiplied by 0.85~* MDRD formula: GFR = 170 x \[SCr\]-0.999 x \[Age\]-0.167 x \[0.762 if subject is female\] x \[1.180 if subject is black\] x \[sun\] -0.170SAlb\]-0.318~* mean Hgb \< 11 g/dL during the screening/baseline period (if subject is not already receiving rHuEPO therapy)~* for subjects currently receiving rHuEPO therapy, the subject must have: a stable rHuEPO dose for the past month; and a rHuEPO frequency of once weekly.~* white blood cell and platelet counts within normal limits~* serum vitamin B12 and folate levels above the lower limit of normal range~* transferrin saturation (TSAT) ≥ 20% during the screening period~* availability for follow-up assessments~* subject must be able to comprehend and be willing to, or have legally accepted representative, give written informed consent for participation in the study~Exclusion Criteria:~* scheduled to initiate dialysis~* uncontrolled hypertension (diastolic blood pressure \> 105 mm Hg or systolic blood pressure of \> 180 mm Hg during the screening/baseline period on two separate measurements)~* clinically unstable in the judgment of the investigator (eg, subject is in the intensive care unit, immediately post-myocardial infarction, etc)~* scheduled to receive a living donor kidney transplant~* treatment of grand mal epilepsy within the past 6 months~* moderate to severe congestive heart failure (NYHA class III or IV)~* clinical evidence of severe secondary hyperparathyroidism (parathyroid hormone level \> 1500 pg/mL)~* severe active chronic inflammatory process (eg, ulcerative colitis, peptic ulcer disease, rheumatoid arthritis, etc)~* currently receiving antibiotic therapy for systemic infection (enrollment may be postponed until the course of antibiotics has ended)~* known aspartate aminotransferase (AST) or alanine aminotransferase (ALT) greater than 3 times the upper limit of the normal range on more than one occasion within three months prior to screening~* known positive HIV antibody or hepatitis B surface antigen~* clinical evidence of current malignancy and/or receiving chemotherapy with the exception of basal cell or squamous cell carcinoma of the skin and cervical intraepithelial neoplasia~* active bleeding or RBC transfusion within eight weeks of enrollment~* androgen therapy within four weeks before enrollment~* known hematologic disease (eg, sickle cell anemia, myelodysplastic syndromes, hematologic malignancy, myeloma; hemolytic anemia, etc)~* any condition that is likely to affect subject compliance~* currently or previously (within 30 days) enrolled in investigational device or drug trial(s) or receiving investigational agent(s)~* the exception to this is if the subject was enrolled in another Aranesp™ or rHuEPO protocol~* pregnant or breast feeding women (women of child-bearing potential must be using contraceptive precautions)~* women planning to have a child during the study period~* known hypersensitivity to the active substance or any of the excipients

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Single arm (Type: EXPERIMENTAL): Every other week dosing of Aranesp SC

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete